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Purpose: Identification of new therapies in small cell lung cancer
(SCLC) is urgently needed. Insulin-like growth factor 1 receptor
(IGF1R) is a tyrosine kinase receptor implicated in the pathogenesis
of several malignancies and is potentially an attractive target for
anticancer treatment. Knowledge about IGF1R protein expression,
gene copy number, and the prognostic relevance of these features in
SCLC is limited.
Methods: We analyzed IGF1R protein expression and gene copy
number in primary tumors from 90 patients with SCLC (67 men and
23 women) who underwent pulmonary resection. IGF1R expression
assessed by immunohistochemistry with H scores from 0 to 400 was
evaluable in 84 patients and IGF1R gene copy number assessed by
silver in situ hybridization technique in 81 patients.
Results: Median H score for IGF1R protein expression was 88
(range, 0–400), and the proportion of positive immunostaining
using cutoff H score of 10 was 74%. Increased IGF1R gene copy
number (an average of four or more copies per cell) was found in 15
cases (18.5%), five of whom (6.2%) showed gene amplification.
There was a significant correlation between protein expression and
gene copy number (r  0.49, p  0.005). IGF1R expression and
gene copy number did not associate with clinicopathological factors
such as patient age, tumor size, lymph node involvement, stage, and
survival.
Conclusions: SCLC is characterized by frequent high-IGF1R pro-
tein expression, increased gene copy number, and occasional occur-
rence of true gene amplification. These features may have important
implications for future anti-IGF1R therapeutic approaches.
Key Words: Lung cancer, IGF1R, Protein expression, Gene copy
number, Prognosis.
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SCLC comprises approximately 15% of new lung cancerdiagnoses in the United States1 and approximately 10 to
20% in Europe. Although the incidence of small cell lung
cancer (SCLC) is slowly decreasing, the cure rates have
increased only slightly over the last decades and remain
elusive.1 Median survival of patients presenting with limited
disease (LD) and extensive disease (ED) is approximately 16
to 24 months and 6 to 12 months, respectively. Novel treat-
ment approaches considering biologic characteristics of this
tumor are, therefore, urgently needed.
The insulin-like growth factor (IGF) pathway regulates
several important cell functions, including cell growth, pro-
liferation, survival, and invasion. The extracellular pathway
components include two ligands (IGF1 and IGF2, produced
under the control of growth hormone), their binding proteins
(IGFBP1-6, governing ligand bioavailability in the circula-
tion, tissue, and cell), and two cell membrane receptors
(IGF1R and IGF2R).2 IGF1R is structurally related to insulin
receptor and has tyrosine kinase activity capable of down-
stream signaling through RAS/RAF/mitogen-activated pro-
tein kinase pathway and phosphatidylinositol-3-kinase-Akt
pathway, whereas IGF2R acts as a decoy receptor. Increased
IGF1R activity results in up-regulation of survivin expres-
sion,3 which could be a potential mechanism of chemoresis-
tance in SCLC.
Because of the paucity of existing data on IGF1R
abnormalities in SCLC, the aim of this study was to evaluate
IGF1R protein expression and gene copy number in this
tumor type in relationship to clinical characteristics and
survival. Because adequate primary tumor specimens of
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SCLC are difficult to obtain and typically small, we used
previously described primary tumor specimens collected dur-
ing a 20-year period from series of patients with LD who
underwent pulmonary resection.4
PATIENTS AND METHODS
Patient Population
Archival formalin-fixed paraffin-embedded tumor sam-
ples were obtained from 90 patients with SCLC who under-
went pulmonary resection between 1982 and 2002 at Medical
University of Gdansk. Because of difficulties in obtaining
reliable biopsy material for histopathological examination,
the diagnosis of SCLC in this group was established only
after the pulmonary resection. In all patients, surgery was
followed by one of the standard chemotherapy regimens.
Patient clinical characteristics are shown in Table 1. Median
follow-up was 86 months (range, 1–211 months), with a
2-year survival probability of 43% and a median survival of
17.8 months.
Tissue Microarray Preparation
On each paraffin-fixed block, a morphologically repre-
sentative SCLC tumor area was identified under the micro-
scope by a pathologist, using a stained hematoxylin and eosin
section on a glass slide as a guide. Tissue microarray was
constructed using manual MTA I Beecher Instrument. Three
0.6 mm cores from different tumor areas were taken for each
patient.
IGF1R Protein Expression
Immunohistochemistry evaluation, on 4 M sections,
was done using the Ventana G11 (CONFIRM, Ventana
Medical Systems, Tucson, AZ) anti-IGF1R antibody follow-
ing the manufacturer’s instructions. Briefly, the staining was
performed on the Ventana BenchMark XT autostainer using
the ultraView detection kit, and the primary antibody was
incubated for 16 minutes. The score was determined accord-
ing to the “hybrid scoring system” (H score) criteria, which
sums the products of the five staining intensity categories
(0–4) by the percentage of positive cells (0–100%). Thus,
the final immunohistochemistry score ranged from 0 to 400.
Two certified pathologists and one reader independently
scored each core.
IGF1R Gene Copy Number
IGF1R gene copy number was evaluated using auto-
mated silver in situ hybridization (SISH), a chromogenic
assay that allows for quantification of gene copy number
concurrent to visualization of cell morphology in brightfield
microscopy. The tissue microarray (TMA) containing tripli-
cate cores per patient was probed according to the Ventana
Medical Systems Inc. (Tucson, AZ) protocols for the IN-
FORM IGF1R DNA probe. The probe was labeled with
dinitrophenol and optimally formulated for use with ultra-
View SISH Detection Kit and accessory reagents on the
Benchmark automated slide stainer. The IGF1R DNA probe
was denatured at 95°C for 12 minutes, and hybridization was
performed at 52°C for 4 hours. After hybridization, three
stringency washes at 72°C were performed. The IGF1R DNA
probe was visualized using a rabbit antidinitrophenol primary
antibody and the ultraView SISH Detection Kit. The detec-
tion kit contained a goat antirabbit secondary antibody con-
jugated with horseradish peroxidase used as the chromogenic
enzyme. The chemistry of the SISH reaction, briefly de-
scribed, is driven by the sequential addition of silver A (silver
acetate), silver B (hydroquinone), and silver C (H2O2). Here,
the silver ions (Ag) are reduced by hydroquinone to me-
tallic silver atoms (Ag). This reaction is fueled by the sub-
strate for horseradish peroxidase, hydrogen peroxide (silver
C). The silver precipitation is deposited in the nuclei, and a
single copy of the IGF1R gene can be visualized as a single
discrete black dot, whereas a tight cluster of black dots
stacked so closely together that individual signals cannot be
resolved are considered amplified IGF1R genes. The speci-
men was then counterstained with Ventana’s Hematoxylin II
and Bluing reagent for interpretation by light microscopy.
The number of IGF1R gene copies per nucleus was deter-
mined by two certified pathologists counting 50 nuclei, or
less if the tissue microarray core was partially depleted, by
two methods. In the first method, termed “focused,” the
pathologists scanned the core and focused on regions that
appeared to have the highest copy numbers and counted 50
nonoverlapping nuclei that had the highest copy numbers. In
the second method, termed “consecutive,” the pathologists
scanned the slide and found a region with high copy number
and counted the signals in 50 consecutive nonoverlapping
nuclei. Individual signals, black dots, were given a score of
one, and if clusters were present, the numbers of signals
within the cluster were estimated based on size of the cluster.
The scores were analyzed to determine the mean of IGF1R
gene copy number per nucleus.
TABLE 1. Patient Characteristics
Characteristics
Age (yr)
Median (range) 57 (37–82)
60, n (%) 38 (42)
Gender, n (%)
Female 23 (26)
Male 67 (74)
Pathological stage, n (%)
IA 6 (7)
IB 26 (29)
IIA 5 (6)
IIB 13 (14)
IIIA 24 (27)
IIIB 12 (13)
Unknown 1 (1)
Surgery type, n (%)
Lobectomy 40 (44)
Pneumonectomy 46 (51)
Segmentectomy 4 (4)
Site, n (%)
Left 43 (48)
Right 47 (52)
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Statistical Analysis
SAS (version 9.2; SAS Institute Inc., Cary, NC) was
used for all statistical analyses. Group comparisons were
conducted using two-sided Pearson’s 2 tests for categorical
data and two-sided Student’s t-tests for continuous data.
Associations between continuous measures were compared
using Pearson’s product-moment correlation coefficient.
Overall survival was calculated as time from surgery to last
follow-up date or death and plotted with 95% confidence
intervals using the Kaplan-Meier method. Differences in
survival between groups were assessed using the log-rank
test. Multivariate Cox proportional hazards regression anal-
ysis was performed adjusting for age, gender, tumor site,
tumor stage, and tumor histology. All tests were considered
statistically significant at p  0.05.
RESULTS
IGF1R Protein Expression
IGF1R protein expression could be evaluated in 84
samples (93%). There was a wide range (0–400) of protein
expression among particular patients based on the H scores
(Figure 1). For each patient, results from three cores, or less
if depleted, were averaged and compared with the core with
the highest score. Figure 2 shows the distribution and fre-
quency of scores, in addition to median and mean, based on
average of cores (Figure 2A) and maximum core (Figure 2B).
There is a very high correlation (r  0.97) between these two
scores, resulting in excellent concordance for protein expres-
sion between all evaluators (r  0.88 D.T.M. versus M.P.,
r  0.95 D.T.M. versus M.W.W., r  0.86 M.P. versus
M.W.W.) using maximum core value (data not shown). Thus,
for further analyses, the scores from the highest core deter-
mined by one of the pathologists (D.T.M.) were used. Median
H score for IGF1R protein expression was 88 (range, 0–400),
and the proportion of positive immunostaining using cutoff H
score of 10 was 74%. There was no significant correlation
between IGF1R protein expression using an H score of 88
(median) and clinicopathological factors (Table 1). No sig-
nificant association was found between IGF1R protein ex-
pression and overall survival using univariate Kaplan-Meier
and log-rank analysis (log rank p  0.83; Figure 4A). The
same held true for the H score considered as a continuous
variable in both the univariate Cox regression (hazard ratio
[HR]: 0.998 [0.996–1.001], p  0.20) and multivariate Cox
regression model adjusted for age, gender, tumor site, tumor
histology, and stage.
IGF1R Gene Copy Number
IGF1R gene copy number assessed by two pathologists
using both the “focused” and “consecutive” methods (see
Patients and Methods section) was evaluable in 81 patients
(90%). The average of the three cores, or less if depleted, for
each patient’s mean of IGF1R genes per nucleus per core was
determined and compared with the core with the highest score
from the same patient. Figure 2 shows histograms, using
scores from one pathologist (S.S.), for average of cores with
focused and consecutive methods and maximum core with
both methods, C-F, respectively. There was a high correlation
between average of the cores and maximum core using either
method (r  0.96, p  0.001, focused; r  0.97, p  0.0001,
consecutive), and similarly, there was a high correlation
between the focused and consecutive methods using either
maximum core or average of cores (r  0.98, p  0.0001,
maximum core; r  0.97, p  0.0001, average of cores).
Similar results were obtained by the second pathologist, and
therefore, for future analysis, for each patient, the core with
highest mean IGF1R gene copy number per nucleus using the
focused method assessed by one pathologist (S.S.) was se-
lected. The median gene copy number was 2.4 (range, 1.3–
18.4). Fifteen patients (18.5%) had four or more copies of
IGF1R per nucleus, and five of those had clusters (amplifi-
cation). Representative pictures showing the range of IGF1R
gene copy number are shown in Figure 3. High IGF1R gene
FIGURE 1. Representative photographs of insu-
lin-like growth factor 1 receptor (IGF1R) protein
expression visualized by immunohistochemistry.
Panel A, no expression (H score, 0); panel B, low
expression (H score, 130); panel C, moderate ex-
pression (H score, 205); and panel D, high expres-
sion (H score, 400). Scores based on reader
D.T.M.
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copy number tended to associate with increased age (p 
0.053), but otherwise, there were no associations with clinical
and pathologic characteristics (Table 2). In the univariate
analysis, IGF1R gene copy number (with the median as the
cutoff between high and low copy number) was not associ-
ated with overall survival (log rank p  0.36; Figure 4B).
Similarly, no impact on survival was found when IGF1R
gene copy number was considered as a continuous variable in
the univariate Cox regression (HR: 1.011 [0.898–1.139], p
0.85) or when included into multivariate Cox regression
model adjusted for age, gender, tumor site, tumor histology,
and stage. Additionally, when considering a cutoff of four or
more copies of IGF1R per nucleus, no association with
survival was found using Kaplan-Meier analysis (log rank
p  0.32), univariate Cox regression (HR: 0.723 [0.367–
1.427], p  0.35), or multivariate Cox model adjusting for
age, gender, tumor site, tumor histology, and stage.
Combined IGF1R Protein Expression and Gene
Copy Number Analysis
At least one core with a valid score for combined
IGF1R protein expression and gene copy number analysis
was obtained in 79 of 90 patients (88%). There was a
significant correlation between IGF1R protein expression and
gene copy number (r  0.49, p  0.005).
DISCUSSION
This study demonstrated that human SCLCs frequently
overexpress IGF1R protein and often have increased IGF1R
gene copy numbers. According to our knowledge, this is the
first study to report true IGF1R gene amplification in SCLC.
Using the cutoff H score of 10, IGF1R protein was present in
74% of patients, whereas the median H score of 88 is
comparable with that in non-SCLC (NSCLC).5,6 The IGF1R
gene copy number was increased in 18.5% of tumors (assum-
ing cutoff point of average gene copies per nucleus 4) and
IGF1R gene amplifications in 6%. In this study, we used 0.6
mm core tissue microarray, which provides sufficient amount
of tumor tissue for adequate protein and gene copy number
assessment. Nevertheless, we cannot exclude the possibility
of missing some focal gene amplifications, when compared
with the whole tissue sections. Thus, the real frequency of
amplification might be higher in larger tumor specimens.
Insulin and insulin-like growth factor have been known
to be essential for SCLC growth for many years, exemplified
by in vitro preclinical studies where SCLC used the HITES
medium including insulin.7 The first data on IGF receptors in
human cancers were published in 1989, and already at that
time, suggestion was made on their role in controlling tumor
growth.8,9 Further studies showed that expression of IGF1
gene is present in various cancer cell lines10 including SCLC,
where expression of IGF1 mRNA was present in 11 of 12
FIGURE 2. Histograms showing distribution,
frequency, median, range, mean, and standard
deviation. A and B, Insulin-like growth factor 1
receptor (IGF1R) protein expression from
reader D.T.M. using either the average of the
cores or the core with maximum H score for
each patient, respectively. C and D, IGF1R gene
copy number for reader S.S. using the average
of the cores value determined by the focused
and consecutive methods. E and F, IGF1R gene
copy number for reader S.S. using the maxi-
mum core value determined by the focused
and consecutive methods.
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analyzed SCLC cell lines.11 There are only a few studies
addressing the influence of IGF1R signaling on SCLC cell
line growth. Activation of IGF1R pathway was reported to
stimulate SCLC cell line proliferation,7 whereas targeting
IGF1R pathway resulted in growth inhibition and induction
of apoptosis.12,13 These effects were also seen when SCLC
cell lines were exposed to novel selective IGF1R tyrosine
kinase inhibitor (TKI) NVP-ADW742.14 Further experiments
demonstrated that NVP-ADW742 combined with imatinib
sensitizes SCLC cells to chemotherapy.15
Improved therapy for SCLC is desperately needed.
Targeting IGF1R receptor is a new promising treatment
strategy in oncology. Two different classes of agents are in
preclinical and clinical development, including monoclonal
antibodies directed against the extracellular domain of IGF1
receptor and TKIs targeting its intracellular domain. Al-
FIGURE 3. Representative photographs of IGF1R
gene copy number visualized by silver in situ hy-
bridization (SISH). Panel A, 2.2 genes per nucleus;
panel B, 3.4 genes per nucleus; panel C, 5.5
genes per nucleus; and panel D, 18.7 genes per
nucleus. Scores based on reader S.S. focused
reading method.
TABLE 2. IGF1R Protein Expression and Gene Copy Number vs. Patient Characteristics
Characteristics
IGF1R Protein Expression IGF1R Gene Copy Number
IGF1R <88 IGF1R >88 p IGF1R <2.4 IGF1R >2.4 p
n 42 42 41 40
Age (yr)
Median (range) 56 (40–81) 61 (37–73) 0.18 55 (40–73) 60 (37–81) 0.05
Gender, n (%)
Female 10 (24) 12 (29) 0.62 9 (22) 0.65
Male 34 (76) 30 (71) 30 (73) 31 (78)
Pathological stage, n (%)
IA 2 (5) 4 (10) 0.76 1 (2) 5 (12) 0.38
IB 11 (26) 12 (29) 9 (22) 12 (30)
IIA 3 (7) 2 (5) 3 (7) 1 (2)
IIB 4 (10) 7 (17) 5 (12) 7 (18)
IIIA 14 (33) 11 (26) 14 (34) 10 (25)
IIIB 8 (19) 5 (12) 8 (19) 5 (12)
Missing 0 1 (2) 1 (2) 0
IGF1R, insulin-like growth factor 1 receptor.
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though studies of IGF1R TKIs are mainly in preclinical
phase,16,17 those using monoclonal antibodies already showed
its potential to inhibit downstream signaling of IGF1R and to
suppress growth of various cell lines.18–20 Anti-IGF1R anti-
body CP-751,871 was tested in monotherapy21 and in com-
bination with chemotherapy in patients with NSCLC in a
randomized phase II study, showing increased response rate,
when compared with chemotherapy alone, with acceptable
safety profile.22
Our results showing the presence of IGF1R protein and
increased IGF1R gene copy number in a proportion of SCLCs
justify further clinical studies using anti-IGF1R approaches in
this tumor. Two randomized studies designed to evaluate the
safety and efficacy of monoclonal antibodies against IGF1R
(CP-751,871 and MK-0646) in combination with standard
chemotherapy in ED SCLC will be activated shortly (avail-
able at: www.clinicaltrials.gov, accessed March 2010).
We did not find any association of IGF1R protein
expression or IGF1R gene copy number with clinical vari-
ables and overall survival. There are no published data on
prognostic impact of IGF1R gene copy number in SCLC,
whereas the data on prognostic significance of IGF1R protein
expression are inconsistent. In one study, IGF1R protein
expression was found to be associated with longer overall
survival in ED SCLC, but not in LD,23 whereas another study
of 124 patients with SCLC failed to show prognostic rele-
vance of this feature.24 No prognostic impact of IGF1R
protein expression was found in surgical series of patients
with NSCLC.6,25 Increased gene copy number has prognostic
value in various malignancies, as exemplified by poor prog-
nosis related to amplification of HER2 in patients with breast
cancer, or high epidermal growth factor receptor (EGFR)
gene copy number in NSCLC.26 The lack of such correlation
in our series may partly be due to patient selection and
nonstandard treatment. Surgery is not a standard therapeutic
option in SCLC, and most patients are diagnosed with bron-
choscopy or fine needle biopsy. In consequence, tumor spec-
imens are often tiny and insufficient for molecular testing. In
our study, SCLC primary tumor samples were obtained from
a unique series of patients treated with surgery, as their
definite diagnosis of SCLC was established only after the
resection. Thus, this group is highly selected with respect to
disease stage and general status and may not be represen-
tative for the overall population of patients with SCLC.
Indeed, prognosis in this group was significantly better in
comparison with patients with disseminated SCLC and
more dependent on local control. Thus, our results should
be interpreted regarding the specific subset of patients and
require confirmation in a typical population of patients
with SCLC.
In this study, we had no detailed information on smok-
ing status. We presume that typically for this tumor virtually
all patients were smokers, but whether they were current or
former smokers could not be established. Thus, we were not
able to correlate IGF-1R protein expression or gene copy
number to detailed smoking history. Nevertheless, in our
previous study in patients with NSCLC, we did not demon-
strate any difference in IGF-1R protein expression or gene
copy number related to former- or current smoking status.6
Similarly, no correlation between IGF1R protein expression
and smoking status was reported in a recent study in SCLC.23
As demonstrated in our study, IGF1R protein expres-
sion is correlated with IGF1R gene copy number, validating
our methodology of IGF1R assessments. Similar findings
were recently reported in NSCLC.6 In this study, we applied
two different scoring methods and came up with highly
consistent results. One minor difference observed was that
with the “focused” assessment, we detected a slightly higher
gene copy number (a median of 2.4 versus 2.2 genes per
nuclei for the cohort) and a few more patients with focal
amplification (5 versus 3), which may reflect the heterogene-
ity of SCLCs.
Our results demonstrating high-IGF1R protein expres-
sion and increased IGF1R gene copy number in SCLC should
indicate that this disease may be considered for therapies
using IGF1R inhibitors. Future studies should include predic-
tive assessment of IGF1R protein and gene copy number for
response and outcome to IGF1R inhibitor therapy.
In summary, our study showed that increased IGF1R
protein expression and increased gene copy number are
common events in SCLC. Furthermore, some patients had
tumors with true IGF1R gene amplification. The lack of
prognostic implications of both protein expression and gene
copy number does not preclude the potential predictive value
of these markers for anti-IGF1R therapies.
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